What are the entry criteria for LEAP?
If a patient is not eligible for another lapatinib clinical trial and has advanced or metastatic ErbB2 overexpressing breast cancer, the patient may be eligible for the EAP. In particular, those patients who have previously received therapies containing anthracycline, taxane and trastuzumab and have progressed on their disease may be eligible. Patients will work with their medical oncologists to determine eligibility. For more information regarding qualification and enrollment in Canada. as well as on additional details on the Lapatinib EAP, please call: 1-888-489-5372. For Europe and International, inquiries from physicians can be directed to the following email address: breastcancereap@gsk.com. Patients should consult their physicians.
